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Abstract: The possible effects of elevation of the plasma phe- 
nylalanine level secondary to the ingestion of aspartame on 
brain amino acid uptake in human subjects have been in- 
vestigated by means of positron emission tomography (PET). 
l-['lC]Aminocyclohexanecarboxylate (["CIACHC) is a 
poorly metabolized synthetic amino acid that crosses the 
blood-brain barrier by the same camer that transports nat- 
urally occumng large neutral amino acids. Quantitative test- 
retest PET studies were performed on 15 individuals. Seven 
received two identical baseline scans, whereas eight received 
a baseline scan followed by a scan performed -40-45 min 
following ingestion of an orange-flavored beverage containing 
34 mg/kg of body weight of the low-calorie sweetener aspar- 
tame, a dose equivalent to the amount in 5 L of diet soft 
drink consumed all at once by the study subjects, weighing 
an average of 76 kg. The 40-45-min interval was selected to 
maximize the detection of possible decreases in ACHC uptake 
resulting from increased competition for the carrier, because 
the plasma phenylalanine level is known to peak at this time. 
We observed an 11.5% decrease in the amino acid transport 
rate constant KI and a smaller decrease in the tissue distri- 
bution volume of ACHC (6%). Under conditions of normal 
dietary use, aspartame is thus unlikely to cause changes in 
brain amino acid uptake that are measurable by PET. Key 
Words: Amino acid transport-Phenylalanine-Aminocy- 
clohexanecarboxylate-Aspartame-Positron emission to- 
mography-Blood-brain barrier. Koeppe R. A. et al. Effect 
of aspartame-derived phenylalanine on neutral amino acid 
uptake in human brain: A positron emission tomography 
study. J. Neurochem. 56, 1526-1535 (1991). 
Entry of many amino acids across the blood-brain 
bamer (BBB) into the brain occurs via a camer-me- 
diated process, the properties of which have been widely 
studied in animal models (Oldendorf, 1970; Oldendorf 
and Braun, 1976; Pardridge, 1977, 1983, 1986; Smith 
et al., 1987). This transport system, referred to as the 
large neutral amino acid (LNAA) carrier system, has 
been shown to transport the essential amino acids. The 
various substrates for the LNAA transport system all 
compete for the same binding site, and the camer op- 
erates near saturation in normal biological conditions 
in the rat, with phenylalanine and leucine accounting 
for more than half of the camer occupancy (Smith et 
al., 1987). 
The dipeptide aspartame (L-aspartyl-L-phenylala- 
nine methyl ester) is a widely used low-calorie sweet- 
ener. Aspartame is hydrolyzed in the human gut, and 
ingestion of large doses is followed by an increase in 
plasma levels of phenylalanine. Because of phenylal- 
anine's high affinity for the LNAA carrier in animals 
(K,  = 11 pmol/L in rat cortex, as measured by Smith 
et al., 1987) and because the LNAA transport system 
normally operates near saturation, an increase in the 
concentration of phenylalanine in the plasma without 
a corresponding rise in the plasma concentrations of 
other essential amino acids might effectively reduce 
transport of these other amino acids across the BBB 
by competitive inhibition. Although the relative affin- 
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ities of amino acids for the LNAA carrier in the human 
BBB are not precisely known in vivo, the competitive 
effect of phenylalanine has been surmised to account 
for the developmental defect in phenylketonuria 
(Kaufman, 1977; Choi and Pardridge, 1986). 
The effects of elevated plasma phenylalanine levels 
on uptake rates of other essential amino acids can be 
monitored by the use of trace amounts of a radiolabeled 
amino acid. Increases or decreases in the transfer rate 
of the radiotracer across the BBB reflect the combined 
effects of all other amino acids competing for the 
LNAA carrier. The effect of an individual amino acid 
on tracer uptake is determined by its K, and its con- 
centration in plasma (Pardridge, 1977). 
To perform these experiments in humans, we de- 
veloped a technique using the positron-emitting radio- 
pharmaceutical probe ’ ‘C-labeled 1 -aminocyclohex- 
anecarboxylate ([ * ‘CIACHC) to measure BBB amino 
acid transport rates and brain distribution volume using 
positron emission tomography (PET) (Koeppe et al., 
1990). We report here findings on the effects of aspar- 
tame-derived phenylalanine on amino acid transport 
(KJ and distribution volume (DV) as determined by 
test-retest PET studies performed on young normal 
human male control subjects. The significance of the 
observed effects and the limitations of the methods used 
to derive our findings are discussed. 
MATERIALS AND METHODS 
PET amino acid uptake studies were performed using 
[ I  ‘CIACHC, which was synthesized via a Bucherer-Strecker 
reaction of cyclohexanone with H1’CN in the presence of 
ammonium carbonate and ammonium chloride according 
to the method of Hayes et al. (1978). After purification by 
ion-exchange chromatography, > 100 mCi of product (cor- 
rected radiochemical yield, - 50%) was typically obtained 
40-50 rnin following bombardment. [“CIACHC was for- 
mulated in normal saline solution and sterilized by filtration 
before administration. The injection volume of a 20 mCi 
dose was 5-15 ml and contained a total ACHC mass of 2-5 
mg (14-35 pmol). Radiochemical purity, as determined by 
radio-HPLC, was in all cases >98%. The absence of unreacted 
cyanide was confirmed by colorimetric assay before admin- 
istration. 
The research protocol was approved by an institutional 
review board (Human Subjects and Radioactive Drug Re- 
search Committees), and informed consent was obtained from 
all subjects before participation in the study. Subjects received 
brief physical and neurological examinations before the PET 
study and were assessed to be in good health. Two sequential 
[“CIACHC PET studies were performed within a 3-4-h in- 
terval in a single morning scanning session on each of 15 
normal male volunteers between the ages of 19 and 33 years. 
Scans were acquired on a TCC PC4600A positron tomograph 
with in-plane resolution of 11-12 mm full-width at half- 
maximum and axial resolution of -10 mm full-width at 
half-maximum. Scanner sensitivity is -20 kcps/pCi/ml in 
a 20-cm phantom. The scanner provided five simultaneous 
tomographic slices separated by 1 1.5 mm. 
Subjects were separated into two groups: a “control” and 
an “aspartame” group. Subjects in both groups fasted over- 
night before the study. All subjects received 300 ml of an 
unsweetened beverage (Wyler’s orange-flavored drink mix; 
Thomas J .  Lipton, Englewood Cliffs, NJ, U.S.A.) before the 
first PET scan (“placebo”). [“CIACHC (10-20 mCi) in 5- 
15 ml of normal saline solution was administered intrave- 
nously in a slow bolus injection (30-60 s). A dynamic se- 
quence of 15 PET scans, covering a total of 60 min, was 
initiated at the time of injection. Approximately 30 rnin to 
1 h following the completion of the first PET study, control 
subjects received an additional 300 ml of unsweetened drink, 
whereas the “aspartame” subjects received the drink con- 
taining, in addition, 34 mg of aspartame/kg of body weight. 
Approximately 40-45 rnin following ingestion of either “as- 
partame” or “placebo,” subjects from both groups were in- 
jected with the second dose (10-20 mCi) of [“CIACHC and 
underwent a repeat PET scan with an acquisition protocol 
identical to that for the first scan. The actual start time for 
the second scan ranged from 35 to 48 rnin following ingestion 
for six of the eight “aspartame” subjects, owing to variations 
in the time of delivery of [“CIACHC. One of the other two 
subjects was inadvertently scanned only 17 rnin following 
aspartame ingestion, whereas the other subject was scanned 
63 rnin after aspartame ingestion, owing to a delay in the 
chemical synthesis. 
Arterial blood samples were withdrawn via a catheter 
placed in the radial artery. Samples were acquired as rapidly 
as possible for the first 2 rnin following [“CIACHC injection 
and then at progressively longer intervals, increasing to 10 
rnin by the. end of the study. Plasma samples, separated from 
red blood cells by centrifugation, were counted in a Nal scin- 
tillation well counter. Additional blood samples were drawn 
before each PET scan, at two times early in each scan, at the 
end of each scan, and at -3-4 h after the second PET scan, 
for determination of plasma amino acid concentrations. 
Plasma samples were placed on ice until the end of the study, 
frozen at -7OoC, and shipped in dry ice to the laboratory of 
Dr. L. Stegink (University of Iowa) for analysis of amino 
acids by the methods of Lee (1974) and Mondino et al. (1975). 
Plasma concentrations were determined for phenylalanine, 
valine, isoleucine, leucine, methionine, histidine, tryptophan, 
and tyrosine. 
Because ACHC is not metabolized in the brain (Aoyagi et 
al., 1988), a two-compartment (plasma and brain) two-rate 
parameter tracer kinetic model was applied to the dynamic 
PET data (Koeppe et al., 1990). The two-parameter fit pro- 
vided estimates of the uptake rate constant, K ,  (ml/g/min), 
describing the carrier-facilitated transport from plasma across 
the BBB, and the clearance rate constant, k2 (l/min), de- 
scribing the rate oftransport from brain back into blood. The 
ratio of these two parameters provides a measure of the ra- 
diotracer’s tissue DV (ml/g). A rapid pixel-by-pixel estimation 
procedure, using weighted integrals (Alpert et al., 1984), was 
used to provide functional images of the uptake and clearance 
rate constants and hence the DV for ACHC. The first 3 rnin 
of data were excluded from the estimation to minimize the 
effect from blood-borne radioactivity in the brain, which is 
large immediately following injection (Koeppe et al., 1990). 
Total calculation time for the estimation routine ( 128 X 128 
pixels, five planes, 15 frames of data) was <5 rnin on a VAX 
750 minicomputer. 
RESULTS 
Table I reports plasma amino acid concentrations 
of the major LNAAs at 2-3 rnin after injection of 
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TABLE 1. Plasma amino acid concentrations at time of PET scan: uspartame subjects 
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Concentrations are given in pmol/L.. Scan 1 is the baseline scan; scan 2 is -45 min following ingestion of 34 mg of aspartame/kg of body 
weight. 
[“CJACHC for both PET scans of each “aspartame” 
subject. Elevation in plasma phenylalanine levels is 
readily apparent following the ingestion of 34 mg of 
aspartame/kg of body weight. Transient increases from 
a mean baseline of 50 pmol/L to a mean peak of 120 
pmol/L are seen, with the peak levels occurring -40- 
45 min postingestion. Plasma concentrations of most 
other amino acids remained relatively unchanged with 
the exception of tyrosine, for which increases ranging 
from 30 to > 100% were measured. Plasma amino acid 
levels in the control subjects did not vary substantially 
during the course of the study. Figure 1 shows typical 
time courses of the ratio of phenylalanine to the sum 
of all seven of the other amino acids measured for both 
a control and an “aspartame” subject. To the extent 
that phenylalanine levels decline over the course of the 
second scan, some assumptions of the model are vio- 
lated, the consequences of which are discussed below. 
Functional images of the amino acid transport rate 
constant (K, )  and DV for [“CIACHC in both a “con- 
trol” and an “aspartame” subject are shown in Fig. 2A 
and B, respectively. One of the five image planes si- 
multaneously acquired by the scanner is shown for a 
baseline-baseline study in Fig. 2A, and that for a base- 
line-aspartame study is given in Fig. 2B. The repeat 
baseline scans of the “control” subject have very similar 
values for transport and DV. Comparison of the two 
scans of the aspartame subject reveals a decline in the 
ACHC transport rate in the brain following aspartame 
ingestion. Of the eight “aspartame” subjects tested, this 
individual demonstrated one of the three highest re- 
sponses to aspartame, with a 25% decline in K1 in brain 
(2 1 % relative to scalp). Note that neither amino acid 
transport nor DV in scalp was substantially affected by 
plasma phenylalanine levels. 
Table 2 shows mean global values of Kl  in brain and 
scalp for both PET scans on each subject. As seen in 
0 100 200 300 400 
Time (min) 
FIG. 1. Typical time courses of the ratio of phenylalanine concen- 
tration in plasma to the sum of all seven of the other LNAAs for 
both a subject receiving two baseline scans (0) and a subject re- 
ceiving aspartame before the second scan (.). The plasma phe- 
nylalanine concentration during the double baseline study was rel- 
atively constant, ranging from 46 to 52 pmol/L, whereas the plasma 
phenylalanine concentration following aspartame administration 
increased from 56 to a peak of 21 1 pmol/L. The scanning intervals 
for each subject are depicted along the time axis. APM, the time 
of aspartame administration for the “aspartame” subject, which 
for this subject was 35 min before the start of the second scan. 
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FIG. 2. Amino acid transport rate 
(TR) and DV in test and retest 
scans in both double baseline and 
aspartame challenge conditions. 
A Functional images of the amino 
acid transport rate constant K1 
(images on the left) and amino 
acid DV (images on the right) for 
[“CIACHC from a subject in the 
“control” group (subject 2; Table 
2). Images are from one of the 
five levels simultaneously ac- 
quired by the scanner. K1 and DV 
were estimated from a two-com- 
partment two-parameter model, 
pixel-by-pixel, from the kinetic 
data sequences. The top pair of 
images is from the first baseline 
scan. The bottom pair of images 
is from the second baseline scan. 
Note the similar patterns and 
global values for both K1 and DV 
in each scan. B A similar set of 
images for a subject in the “as- 
partame” group (subject 8; Table 
2). The top two images are again 
from a baseline scan. The bottom 
two images are from a retest scan 
following bolus ingestion of 34 mg 
of aspartame/kg of body weight. 
Note the global decline in brain 
values of ACHC TR seen in the 
retest scan (bottom left), whereas 
the TR values in scalp are rela- 
tively unchanged. This subject 
was one of the three highest re- 
sponders to the aspartame chal- 
lenge. 
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TABLE 2. Global values of amino acid transport rate constant, K, (ml/g/min), in brain and scalp 
Brain Scalp 
% difference 
Subject Scan 1 Scan 2 ?6 difference Scan I Scan 2 brain/scalp 
Control subjects 
1 0.039 0.039 0.2 0.037 0.034 8.5 
2 0.037 0.036 -2.7 0.034 0.033 0.8 
3 0.03 I 0.033 4.5 0.034 0.036 -1.9 
4 0.034 0.034 -1.2 0.037 0.032 12.3 
5 0.025 0.022 - 10.0 0.032 0.027 6.4 
6 0.035 0.030 -15.1 0.038 0.029 4.1 
7 0.037 0.038 3.0 0.030 0.033 -5.7 
Mean f SD 0.034 t 0.005” 0.033 f 0.006“ -3.0 t 7.1 0.034 f 0.003’ 0.032 & 0.003’ 3.5 f 6.2 
Aspartame 
1 0.032 0.03 1 -3.5 0.042 0.04 1 -1.6 
2 0.03 1 0.026 - 14.0 0.027 0.028 -17.1 
3 0.028 0.022 -20.6 0.029 0.030 -22.8 
4 0.026 0.02 I -17.4 0.025 0.027 -22.7 
5 0.034 0.030 -11.4 0.033 0.033 -7.4 
6 0.027 0.029 7.3 0.039 0.041 1.8 
7 0.038 0.034 -8.0 0.034 0.03 1 -0.7 
8 0.034 0.026 -25.5 0.036 0.033 -20.6 
Mean ? SD 0.03 1 f 0.004‘ 0.028 f 0.004‘ -1  1.6 t 10.4 0.034 t 0.006“ 0.033 t 0.006“ -11.4 f 10.5 
Scan 1 is a baseline scan in both groups of subjects; scan 2 is a baseline scan in the “control” group and is a challenge scan following ingestion 
of 34 mg of aspartame/kg of body weight in the “aspartame” group. Percent differences are given for brain and brain/scalp as 100 X (scan 2 
- scan I)/scan 1. 
a Paired t = -1.09, p > 0.05 (not significant). ’ Paired f = - 1.60, p > 0.05 (not significant). 
‘Paircd f = -3.19, p = 0.02. 
dPaired t = -0.24, p 0.05 (not significant). 
Fig. 2, the transport rate of [“CIACHC in scalp appears 
to be as high as in brain, a finding indicating a high 
extraction fraction, because PET measures of blood 
flow in scalp are quite low compared with brain. This 
observation and the lack of influence of plasma amino 
acid levels on the scalp transport rate suggest that sim- 
ple diffusion or very-low-affinity uptake is the dominant 
mode of uptake in scalp, rather than camer-mediated 
transport. Thus, the scalp may serve to provide nor- 
malized or relative values of transport. Global means 
of K I  in brain ranged from 0.022 to 0.039 ml/g/min 
in “control” subjects. If it is assumed that the global 
mean cerebral blood flow in normal subjects ranges 
from 0.4 to 0.6 ml/g/min, this indicates that the single- 
pass extraction fraction is < lo%, because extraction 
equals K1 divided by cerebral blood flow. Also shown 
is the percent change in mean K I  from the second PET 
scan relative to the first for each subject. Changes in 
both the absolute value of whole brain K I  and in K I  
normalized to scalp, i.e., the change in the brain-to- 
scalp ratio of K I ,  are given. Absolute changes in K I  
between the test-retest scans on “control” subjects de- 
creased by an average of 3% (range, -15 to +5%), 
whereas changes between scans on “aspartame” sub- 
jects decreased by an average of 12% (range, -25 to 
+7%). Transport changes in brain relative to scalp in- 
creased by an average of 3% between scans in the “con- 
trol” group (range, -6 to +12%), whereas relative 
changes in the “aspartame” group decreased by an av- 
erage of 1 1% (range, -22 to +2%). These changes were 
significant at p < 0.05 (paired t test) in the “aspartame” 
group for both absolute and normalized data but were 
not significant in the “control” group. 
Table 3 shows mean and SD values for regional val- 
ues of transport rate for the test-retest studies of each 
group. Decreases in the range of 10% were seen in all 
brain structures examined following aspartame inges- 
tion with minimal regional variation. Scalp, as antic- 
ipated, showed no response following aspartame inges- 
tion. Cerebellum exhibited a lesser and more variable 
decline than other brain regions, which did not reach 
statistical significance. In contrast, the “control” group 
exhibited no significant differences between first and 
second scans in any of the regions examined. Table 4 
presents regional brain values normalized to scalp, with 
findings similar to those obtained from the absolute 
data reported in Table 3. Also reported in the last two 
columns of Table 4 are between-group comparisons 
for both scan 1 (baseline vs. baseline) and scan 2 (base- 
line vs. aspartame challenge), which further validate 
the effect of aspartame on amino acid uptake. 
Table 5 reports mean global values for ACHC DV 
and clearance rate constant for the two scans of each 
subject. Both DV and kz were decreased in the “as- 
partame” group but by lesser amounts than observed 
in K I  (see Table 2) and with statistical significance only 
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TABLE 3. Regional transport rate constant values for ("CJACHC 
Aspartame subjects Control subjects 
(n = 8) (n = 7) 
Paired Paired 










0.031 f 0.004 
0.033 f 0.006 
0.043 f 0.007 
0.033 f 0.005 
0.032 f 0.005 
0.033 f 0.006 
0.031 f 0.003 
0.035 f 0.005 
0.037 f 0.004 
0.028 f 0.004 
0.033 f 0.006 
0.039 f 0.009 
0.029 k 0.005 
0.028 t 0.005 
0.029 f 0.005 
0.028 f 0.004 
0.031 f 0.006 










0.034 f 0.005 
0.034 f 0.003 
0.044 f 0.006 
0.037 f 0.005 
0.036 f 0.006 
0.036 f 0.006 
0.034 f 0.006 
0.039 f 0.006 
0.037 f 0.006 
0.033 f 0.006 
0.032 f 0.003 
0.043 t 0.007 
0.036 f 0.005 
0.036 k 0.008 
0.036 f 0.007 
0.033 f 0.006 
0.038 f 0.008 







- I .02 
0.01 
0.29 
Data are mean f SD values. K, values are given in ml/g/min. 
p < 0.05 by two-tailed paired Student's 1 test. 
b p  < 0.01 by two-tailed paired Student's t test. 
in DV. No significant differences between scans were 
observed in either DV or k2 for the "control" group. 
DISCUSSION 
PET makes possible the application of biochemical 
methods to the study of regional brain function here- 
tofore restricted to experiments that require direct in- 
tervention and processing of the brains of experimental 
animals (Frey, 1989). The noninvasive property of PET 
is advantageous for the obvious reason that many phy- 
siopathologic conditions are known to occur only in 
humans and would not otherwise be amenable to direct 
biochemical study. In addition, noninvasive ap- 
proaches make it possible for the same individual to 
serve as both control and experimental subject in a 
test-retest experimental design. The test-retest design 
thus has the potential additional advantage that vari- 
ation in experimental parameters measured repetitively 
in the same subject may be less than it is between sub- 
jects. 
TABLE 4. Regional transport rate 
In the present study the test-retest design is used to 
investigate the possibility that ingestion of a large 
amount of aspartame over a brief interval measurably 
affects brain uptake of amino acids that compete with 
phenylalanine for BBB transport via the LNAA carrier. 
Animal studies have demonstrated this competitive ef- 
fect, i.e., an increase in the amount of one plasma 
amino acid causes decreases in BBB uptake of the other 
amino acids. Consequently, such an amino acid im- 
balance might affect protein or neurotransmitter syn- 
thesis in the brain. This mechanism has been proposed 
as the primary cause of the adverse developments seen 
in phenylketonuria. It has been suggested that a similar 
problem might arise from aspartame ingestion, because 
this substance can also produce transient increases in 
plasma phenylalanine levels (Choi and Pardridge, 
1986). In vitro methods, using isolated human brain 
capillaries, have indicated that both high- (K, = 0.26 
Fmol/L) and low- (K, = 22.3 pmol/L) affinity carrier 
systems exist for phenylalanine (Choi and Pardridge, 
1986), and it was suggested that the low-affinity carrier 
:onstant values normalized to scalp 
Aspartame subjects Control subjects Aspartame vs. 
(n = 8) (n = 7) control 
Scan 1 Scan 2 Paired Scan 1 Scan 2 Paired Scan 1 Scan 2 
Reejon baseline aspartame I value baseline 1 baseline 2 t value I value t value 
Whole brain 0.96 f 0.16 0.84 f 0.13 -2.98" 0.99 f 0.14 1.03 f 0.12 1.55 0.43 2.79" 
Cerebellum 1.30 + 0.12 1.19 f 0.22 -1.34 1.29 f 0.22 1.33 f 0.15 0.86 0.13 1.44 
Temporal 1.01 f 0.17 0.89 f 0.17 -3.84' 1.09 f 0.16 1.11 f O . 1 1  0.68 0.88 2.87" 
Frontal 0.99 f 0.15 0.86 f 0.16 -3.53' 1.05 f 0.17 1.13 f 0.20 1.69 0.66 2.94" 
Parietal 1.01 f 0.16 0.88 f 0.13 -2.54" 1.05 f 0.17 1.11 f0 .17 1.85 0.42 2.97" 
Caudate 0.97f0.16 0.85k0.18 -4.10' 1.OOfO.19 1.03 f 0.15 0.87 0.34 2.00 
Putamen 1.09 f 0.17 0.95 f 0.20 -2.42" 1.13 f 0.19 1.17 f 0.19 0.99 0.48 2.28" 
Thalamus 1.14 f 0.18 0.91 f 0.24 -3.72b 1.08 f 0.19 1.14 f 0.18 1.66 0.62 2.14 
Data are mean and SD values of normalized K,. Paired t tests are within-group comparisons; unpaired t tests are between-group comparisons. 
a p < 0.05 by two-tailed Student's t test. 
b p  < 0.01 by two-tailed Student's t test. 
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TABLE 5 .  Global values of amino acid DV and clearance rate constant, k l ,  in brain 
Subiect 
DV (ml/g) k2 (I/min) 









































0.035 k 0.005’ 
Aspartame 
1 0.68 0.72 0.046 0.043 
2 I .04 0.92 0.030 0.029 
3 0.89 0.78 0.03 I 0.029 
4 0.7 1 0.7 I 0.036 0.030 
5 1.02 0.88 0.033 0.034 
6 0.90 0.98 0.030 0.030 
7 1.06 0.82 0.035 0.042 
8 1 . 1 1  1.06 0.03 1 0.024 
Mean -I SD 0.93 C 0.16‘ 0.86 k 0.12‘ 0.034 k 0.006d 0.033 k 0.007d 
Scan 1 is a baseline scan in both groups of subjects; scan 2 is a baseline scan in the “control” group and is a challenge scan following ingestion 
of 34 rng of aspartame/kg of body weight in the “aspartame” group. 
Paired f = 0.70, p > 0.05 (not significant). 
Paired 2 = -1.67, p > 0.05 (not significant). 
Paired t = -3.0, p = 0.03. 
Paired t = -0.36, p > 0.05 (not significant). 
is primarily responsible for mediating amino acid 
transport from blood to brain. More recent work (Har- 
greaves and Pardridge, 1988), also using isolated hu- 
man brain capillaries, reported K ,  values for the high- 
affinity carrier of seven other neutral amino acids in 
addition to phenylalanine, with values ranging from 
0.30 pmol/L for phenylalanine to 8.8 pmol/L for va- 
line, and favors the possibility that the high-affinity 
carrier mediates amino acid entry into the brain. 
Because the affinities of amino acids for the LNAA 
carrier in the human have not been precisely deter- 
mined in vivo, the magnitude of any effect of aspartame 
on amino acid uptake across the human BBB cannot 
be precisely estimated without experimental investi- 
gation, such as is reported here. The dose selected for 
this study, 34 mg of aspartame/kg of body weight, was 
the 99th percentile of estimated consumption before 
the approval of aspartame by the Food and Drug Ad- 
ministration in 1981. This dose is equivalent to the 
amount of aspartame in - 5  I, of diet soft drink bev- 
erage sweetened with aspartame consumed at a single 
sitting by the study subjects, whose mean weight was 
76.3 kg. This assumes that 1 L, of sweetened beverage 
contains 500 mg of aspartame (Homler, 1984). This 
level is well above the current 90th percentile of actual 
aspartame consumption for all ages (2-4 mg/kg/day, 
depending on the age) over the course of a day by a 
typical user of the sweetener (Butchko and Kotsonis, 
1989). It has been estimated that if aspartame replaced 
all dietary sucrose, typical consumption would be -8.3 
mg/kg of body weight/day (Food and Drug Adminis- 
tration, 198 1). The 34 mg/kg dose also approaches the 
solubility limit of aspartame in a reasonable volume 
of a cold aqueous drink to be consumed at once. 
[ I  ICIACHC, a nonmetabolizable synthetic amino 
acid with an affinity for the LNAA carrier in rats similar 
to that of several of the essential amino acids, was se- 
lected as a suitable agent to measure rates of BBB 
transport. Washburn et al. (1981) proposed that 
[“CIACHC would have an affinity for transport similar 
to those of many of the natural amino acids transported 
by the LNAA carrier. Work by Aoyagi et al. (1988) has 
since demonstrated that the V,,, (9 X lo4 pmol/s/g) 
and K,  (53 pmol/L) for transport of ACHC at the rat 
BBB are indeed close to those of tyrosine, methionine, 
and isoleucine. An advantage of the use of a nonme- 
tabolized amino acid analog such as ACHC for mea- 
suring the transport process compared with the use of 
a natural amino acid is that the interpretation of its 
kinetics is relatively straightforward, because there is 
no need to compute breakdown of tracer or incorpo- 
ration into proteins that results in multiple chemical 
forms of the radiolabel. Also, because there are no 
asymmetric carbon atoms in [ I ’CIACHC, separation 
of stereoisomers is unnecessary. Koeppe et al. (1990) 
have recently shown [“CIACHC to be a useful agent 
for the in vivo measurement of BBB amino acid trans- 
port rate and brain DV using dynamic PET. 
The transport rate of [“CIACHC, like that of a given 
natural amino acid, is determined by the product of 
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its transport rate constant, K l  , and its plasma concen- 
tration. Thus, because the concentration of phenylal- 
anine increases selectively following ingestion of as- 
partame, the change in transport rate of another es- 
sential amino acid will be directly proportional to the 
change in its KI . The K I  for a particular amino acid is 
primarily determined by two factors: the amino acid's 
affinity for the LNAA carrier and the total level of 
competition for the carrier from all other amino acids. 
Because an amino acid's affinity for the carrier is a 
fixed value, the magnitude of the decrease in the trans- 
port rate of ["CIACHC, or any other LNAA, is related 
to the total level of competition. Thus, as long as the 
plasma level of any particular amino acid does not 
change, the decrease in ACHC uptake provides a mea- 
sure of the decrease in uptake of that amino acid. 
- Because aspartame ingestion selectively raises plasma 
phenylalanine (and, to a lesser extent, tyrosine) levels, 
decreases in uptake of ["CIACHC can be ascribed to 
the increase in plasma phenylalanine level. It should 
be borne in mind that other dietary effects on plasma 
amino acid levels, such as would follow protein (Fern- 
strom et al., 1979) or carbohydrate (Martin-Du Pan et 
al., 1982; Hurwitz, 1989) ingestion, could produce 
similar or greater changes in ACHC uptake. The effects 
on another amino acid under these conditions would 
depend on the change in its plasma concentration rel- 
ative to the change of the other LNAA plasma con- 
centrations. In such situations, decreases in ACHC up- 
take would be predictive only of those amino acids 
whose plasma levels had not been altered substantially. 
The variability of plasma phenylalanine responses 
to ingestion of aspartame can be seen in Table 2. Re- 
sults are presented for both absolute values (in ml/g/ 
min) and for values normalized to scalp. Even though 
the absolute transport rates are of primary interest in 
this study, it is generally accepted that the greatest single 
source of variability in PET measurements is of a global 
nature (Fox et al., 1984; Mazziotta et al., 1985; Duara 
et al., 1987; Moeller et al., 1987), and PET data are 
therefore often normalized. The sources of this global 
variability in PET data are not entirely understood, 
although they very likely include (a) variation in whole 
brain physiology among individuals, (b) variation in 
whole brain physiology at different times for the same 
individual, and (c) errors in the determination of the 
arterial concentration time course of the radiotracer, 
which cause nearly uniform biases across the brain. 
Normalization of data would not affect detection of 
possible regional differences in uptake (or DV) of 
ACHC or of alterations in regional uptake patterns fol- 
lowing aspartame ingestion. It should be noted that 
regional differences are detected, with gray matter 
structures having roughly twice the Kl values found 
for white matter (Koeppe et al., 1990), whereas DV 
differences between gray and white matter are much 
smaller. However, substantial alterations in regional 
patterns of ["CIACHC uptake or DV were not detected 
following aspartame ingestion (Tables 3 and 4). In 
[ I  'CIACHC autoradiograms in the marmoset (Wash- 
bum et al., 1982), the distribution observed corre- 
sponded to that seen for amino acid incorporation into 
protein, a result suggesting that regional distribution 
of the LNAA camer corresponds to synthetic capacity. 
Because amino acid transport from blood into scalp 
does not appear to be dependent on a saturable process 
in the normal range of plasma amino acid levels, nor- 
malizing brain values to that for the scalp was consid- 
ered to be potentially useful in this test-retest study. 
Significance levels in test-retest scans using such nor- 
malized data (Table 4) were little different than those 
obtained using absolute data, in spite of the fact that 
scalp uptake rates did not vary between scans. This 
may, in part, reflect that different brain regions are 
more tightly coupled to one another physiologically 
than are a brain region and a nonbrain region, such as 
the scalp. 
One of the major limitations of the test-retest scan 
design, as implemented in our study, concerns an in- 
herent assumption of the kinetic model. That is, the 
model parameters being estimated, namely, KI and 
DV, must remain constant throughout the time course 
of the PET measurement. As can be seen in both Fig. 
1 and Table I ,  plasma phenylalanine levels were not 
stable during the course of the second PET scan in 
those subjects who were given aspartame. Therefore, 
we expect that the parameter we are most interested 
in measuring does indeed vary during the course of 
the PET scan. Phenylalanine levels in brain tissue will 
also vary but with a different temporal course than 
plasma levels. Thus, we also expect the clearance rate 
to vary but in a different manner than K I .  Finally, 
because the estimate of DV is given by the ratio of K,/ 
k2,  we also expect it to vary over time as well. 
A 45-min postprandial peak of plasma phen ylalanine 
concentration was anticipated (Stegink et al., 1977), 
thus dictating the time for injection of the second 
["CIACHC dose. It was also anticipated that plasma 
phenylalanine levels would decline as brain uptake of 
["CIACHC progressed. The estimate of K 1  then be- 
comes a weighted average of the values of the transport 
rate over the course of the experiment, with the estimate 
being most strongly influenced by the values shortly 
after ["CIACHC injection, at which time the plasma 
phenylalanine levels were presumably highest. Thus, 
the KI values reported in this study primarily reflect 
the transport rate during the peak of competitive in- 
hibition. At times substantially earlier or later, the ob- 
served effect should be smaller. This is supported by 
the fact that subject 7 of the "aspartame" group (Table 
2), whose scan was started t 2 0  min following aspar- 
tame ingestion (rather than 40-45 min), exhibited very 
little change in the estimated transport rate or DV, and 
the subject whose scan was started 1 h following as- 
partame ingestion (subject 2) exhibited moderate de- 
clines. The three persons who demonstrated the greatest 
responses (subjects 3,  4, and 8) were all scanned be- 
tween 35 and 45 min after aspartame ingestion. 
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The temporal order of the baseline and aspartame 
scans could not be reversed conveniently, as would be 
desirable in a randomized experimental design, because 
of the finite time required for plasma phenylalanine 
levels to return to baseline following administration of 
aspartame. One must, therefore, consider whether the 
order of the scans might have caused the observed de- 
creases in BBB transport. Results presented in Table 
4 offer support that the order of the studies does not 
explain the observed decreases. Comparison of each 
subject’s first PET scan between “control” and “as- 
partame” groups (both baseline scans) showed no sta- 
tistically significant differences (by unpaired Student’s 
t test), whereas comparisons of the retest scans (baseline 
scans for the “control” group vs. aspartame challenge 
scans for the “aspartame” group) demonstrated sig- 
nificant differences near the p < 0.05 level in amino 
acid transport in all brain regions examined except the 
cerebellum. Scalp values, as expected, were not signif- 
icantly different between groups in either the first or 
second scan. 
These experiments demonstrate the suitability of 
[“CIACHC, a nonmetabolized amino acid analog, for 
the evaluation of regional uptake of physiologically 
important amino acids in human brain by means of 
positron emission techniques. Using large oral doses 
of aspartame, we were able to demonstrate small but 
measurable decreases in LNAA uptake. The values for 
the transport rate constant, K,  , from ACHC pre- and 
post-ingestion of aspartame can be used to calculate 
the Ki for competing phenylalanine provided that Ki 
values are known (or assumed) for the other competing 
amino acids. Using K, values of the amino acids re- 
ported for rats (Aoyagi et al., 1988), a Ki in human for 
phenylalanine in the range of 50 hmol/L was estimated 
from subjects in the “aspartame” group. Although a 
Ki value for phenylalanine theoretically can be calcu- 
lated for each individual’s pair of studies, the minimal 
nature of the effect of aspartame and the variability 
encountered discourage making such a calculation. The 
K, for phenylalanine reported in the rat was 1 1  pmol/ 
L (Aoyagi et al., 1988), whereas the K ,  for the low- 
affinity transport system in human brain was reported 
to be 22.3 pmol/L (Choi and Pardridge, 1986). 
The [“CIACHC technique should prove beneficial 
for further in vivo human studies, such as the mea- 
surement of the kinetic parameters of brain amino acid 
uptake, as well as DV. For this, a higher level of plasma 
phenylalanine and thereby of LNAA transport inhi- 
bition than is achievable with aspartame is desirable. 
This can be accomplished by oral administration of 
phenylalanine itself, rather than aspartame. 
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